Hydralazine moa in anti hypertensive

Reading File

Finding Sources

Searching PubMed

hydralazine mechanism action vasodilation

Finding Sources

Reading File

Finding Sources

Loading Image

Here is a thorough breakdown of hydralazine's mechanism of action as an antihypertensive:

Hydralazine - Mechanism of Action

Primary Mechanism: Direct Arteriolar Vasodilation

Hydralazine is a direct-acting vasodilator that selectively relaxes arteriolar smooth muscle (resistance vessels), with little to no effect on venous capacitance vessels.

The exact molecular mechanism is not fully understood, but two key pathways are established:

1. K-ATP Channel Activation

Hydralazine activates ATP-sensitive potassium (K-ATP) channels in vascular smooth muscle
This leads to hyperpolarization of the smooth muscle cell membrane
Hyperpolarization inhibits voltage-gated calcium channels, reducing Ca²+ influx
The net result is decreased intracellular Ca²+ → smooth muscle relaxation → vasodilation
This effect is seen predominantly in coronary, cerebral, splanchnic, and renal vascular beds

(Barash's Clinical Anesthesia, p. 1000)

2. Antioxidant / Nitric Oxide (NO) Preservation

Hydralazine has antioxidant properties - it inhibits reactive oxygen species (ROS) and oxidases
By blocking ROS production, hydralazine prevents the breakdown of endogenous NO (and exogenous NO from drugs like isosorbide dinitrate)
Enhanced NO availability activates soluble guanylate cyclase (sGC) → increased cGMP → activation of protein kinase G (PKG) → vasodilation
This is why hydralazine is often combined with isosorbide dinitrate: isosorbide provides the NO, hydralazine prevents its oxidative degradation

(Lippincott Pharmacology; Fuster's The Heart, 15th Ed.)

Hemodynamic Effects

Effect	Result
Arteriolar dilation	↓ Systemic vascular resistance (SVR)
↓ Afterload	↑ Cardiac output
No venous dilation	Preload (LV) relatively preserved
Baroreceptor activation	Reflex tachycardia
↓ Renal vascular resistance	Maintained/increased renal blood flow

Compensatory/Reflex Responses (Important!)

Because hydralazine drops blood pressure via peripheral vasodilation, the body triggers three compensatory responses:

Reflex tachycardia - baroreceptor-mediated; the magnitude is often greater than expected and may partly reflect a direct CNS effect on cardiovascular regulation
Fluid/sodium retention - activation of the renin-angiotensin-aldosterone system (RAAS) due to reduced renal perfusion pressure
Increased cardiac output - from the tachycardia + reduced afterload

These compensatory responses are why hydralazine is rarely used as monotherapy - it is almost always combined with a beta-blocker (to blunt tachycardia) and a diuretic (to counteract sodium retention).

Diagram - Hydralazine's NO Preservation Role

Hydralazine antioxidant mechanism and NO/cGMP pathway

Hydralazine blocks inflammation-mediated NO breakdown, preserving the NO → sGC → cGMP → PKG → vasodilation cascade (Lippincott Illustrated Reviews: Pharmacology)

Summary of MOA in One Sentence

Hydralazine lowers blood pressure by directly relaxing arteriolar smooth muscle via K-ATP channel activation (reducing intracellular Ca²+) and antioxidant-mediated NO preservation (enhancing cGMP-mediated vasodilation), selectively reducing afterload with a compensatory reflex tachycardia and fluid retention that requires co-administration of a beta-blocker and diuretic.

Clinical Uses Tied to MOA

Hypertensive urgency (IV/IM), especially in pregnancy (preeclampsia/eclampsia)
Chronic HF (combined with isosorbide dinitrate) - particularly beneficial in African Americans intolerant of ACE inhibitors/ARBs
Perioperative hypertension - when tachycardia is absent

Nitrates mos

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Loading Image

Here is a complete breakdown of the mechanism of action of nitrates:

Nitrates - Mechanism of Action (MOA)

Drug Class

Organic nitrates: Nitroglycerin (GTN), Isosorbide dinitrate (ISDN), Isosorbide mononitrate (ISMN)

Step-by-Step Molecular Mechanism

Step 1: Bioactivation to Nitric Oxide (NO)

Organic nitrates enter vascular smooth muscle cells and are metabolized (reduced) to release nitric oxide (NO) - or nitrite, which is further reduced to NO
This requires enzymatic bioactivation (primarily via mitochondrial aldehyde dehydrogenase - ALDH2)
NO can also be formed from the nitrite metabolite

Step 2: Activation of Soluble Guanylyl Cyclase (sGC)

Released NO diffuses into vascular smooth muscle cells and binds to the heme moiety of soluble guanylyl cyclase (sGC)
This activates sGC, converting GTP → cGMP (cyclic guanosine monophosphate)

Step 3: cGMP-Mediated Smooth Muscle Relaxation

Elevated cGMP activates cGMP-dependent protein kinases (PKG)
PKG phosphorylates myosin light chain kinase (MLCK), inactivating it
Inactivation of MLCK → decreased intracellular Ca²+ → smooth muscle relaxation → vasodilation

NO → sGC → cGMP → smooth muscle relaxation pathway

Nitroglycerin (glyceryl trinitrate) enters smooth muscle cells, metabolizes to nitrite → NO → activates guanylyl cyclase → cGMP → cGMP protein kinases → relaxation (Harper's Illustrated Biochemistry)

Vascular Selectivity: Veins > Arteries

Vessel	Effect	Clinical Consequence
Veins (capacitance)	Strong dilation at low doses	↓ Venous return → ↓ Preload → ↓ LV filling pressure
Arteries (resistance)	Dilation at higher doses	↓ Afterload → ↓ SVR
Coronary arteries	Dilation (even at low doses)	↑ Coronary blood flow, relief of vasospasm

At therapeutic doses, venodilation predominates - this is the key anti-anginal mechanism
Arteriolar dilation occurs at higher doses, used in acute heart failure and hypertensive emergencies

(Morgan & Mikhail's Clinical Anesthesiology, p. 470)

How Nitrates Relieve Myocardial Ischemia

Nitrates reduce the O₂ supply-demand mismatch by:

↓ Preload - venous pooling in capacitance vessels → ↓ ventricular end-diastolic pressure → ↓ myocardial wall tension → ↓ O₂ demand + improved subendocardial perfusion
↓ Afterload (at higher doses) - arteriolar dilation → ↓ LV end-systolic pressure → ↓ O₂ demand
↑ Coronary blood flow - direct coronary artery dilation + collateral vessel dilation → redistribution of flow to ischemic subendocardium
Relief of coronary vasospasm - important in Prinzmetal (variant) angina

(Fuster & Hurst's The Heart, 15th Ed.; Goldman-Cecil Medicine)

Additional effect: NO inhibits platelet aggregation (via cGMP in platelets) - antithrombotic benefit.

Tolerance (Tachyphylaxis)

Continuous nitrate exposure leads to tolerance - reduced vasodilatory response
Mechanism: depletion of sulfhydryl (-SH) groups needed for NO bioactivation; oxidative stress and ALDH2 inhibition
Prevention: 8-12 hour nitrate-free interval daily (typically overnight)

(Goldman-Cecil Medicine)

Pharmacokinetics Summary

Drug	Route	Onset	Duration	Notes
Nitroglycerin (GTN)	Sublingual	1-3 min	20-30 min	First-pass hepatic metabolism, bypassed sublingually
Nitroglycerin	IV infusion	Immediate	Infusion-dependent	Used in ACS, acute HF
Nitroglycerin	Transdermal patch	Slow	24 h	Tolerance risk - needs patch-free period
Isosorbide dinitrate (ISDN)	Oral	30-60 min	4-6 h	Requires twice-daily dosing with gap
Isosorbide mononitrate (ISMN)	Oral	30-60 min	8-12 h	Active form, no first-pass metabolism

Metabolized by glutathione-organic nitrate reductase in liver and blood
Nitrite metabolite can convert Hb → methemoglobin (rarely clinically significant; treat with IV methylene blue)

Key Clinical Uses

Stable angina - sublingual GTN for acute attacks; long-acting nitrates for prophylaxis
Unstable angina / NSTEMI - IV nitroglycerin for ongoing ischemia
Acute decompensated heart failure - venodilation reduces pulmonary congestion
Hypertensive emergency - IV nitroglycerin
Esophageal spasm - smooth muscle relaxation
Combined with hydralazine in HF (ISDN + hydralazine - especially in African Americans intolerant of ACE-I/ARB)

Side Effects (Direct from MOA)

Headache - cerebral vessel dilation (most common)
Hypotension / dizziness - excess venodilation
Reflex tachycardia - baroreceptor response to BP drop
Flushing - cutaneous vasodilation
Methemoglobinemia - rare, with high doses
Tolerance with continuous use

Contraindication

Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadalafil) - both raise cGMP via different mechanisms; combined use causes severe hypotension

This is a shared conversation. Sign in to Orris to start your own chat.